Basel, Switzerland — Lonza reported a positive start, led by its contingent of healthcare businesses, during its quarterly earnings call.
The former Capsugel business, now part of Lonza Pharma & Biotech and Lonza Consumer Health, performed well in the first quarter of 2018, with integration continuing as planned, following good progress on business and functional integration.
Key highlights of the report include the following:
  • Continued strong demand for pharma offerings in Clinical Development and Manufacturing and Commercial Manufacturing and for Consumer Health offerings
  • Start of production in the world’s largest dedicated cell-and-gene-therapy manufacturing facility in Pearland, Greater Houston, TX adds to global technology footprint and innovative offerings
  • Announcing mid-scale biologics manufacturing expansion and state -of-the-art technological advances at Lonza's Portsmouth, NH site
  • First milestone achieved for a positive half-year result 2018
“Our businesses along the healthcare continuum produced positive results. Former Capsugel businesses, in particular, performed above our expectations both versus prior year and on a run-rate basis and contributed to our core activities,” said Richard Ridinger, Lonza’s CEO. “We have further strengthened our technology footprint by adding to our portfolio the world’s largest dedicated cell–and-gene-therapy manufacturing facility in Pearland, Texas, and by expanding our mid-scale mammalian capacity in Portsmouth, we will continue to invest into our innovative offerings, global presence, commercial and operational excellence while reviewing our portfolio as part of our long-term strategic growth path.”